Avoro News

Avoro Capital Updates

We are pleased to share industry insights and updates on Avoro and our portfolio companies. Please reach out if you would like to learn more.

Corvus Pharmaceuticals Completes $75 Million Series B Financing

Funds will Advance Company’s Immuno-Oncology Small Molecule and Antibody Programs Burlingame, CA, September 29, 2015 – Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, today announced that it closed a $75 million Series B financing. The transaction was led by …

Read More

Oncobiologics Secures $31 Million Financing

Releasefaa9345b-168e-47b5-8d3e-2b4b4a581492_2150864.pdf Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs. The investment round was led by new investor, Perceptive Advisors. Participating new investors …

Read More

Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing

Investor syndicate includes leading biotech and mutual funds. HOUSTON–BUSINESS WIRE–Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announced the successful completion of a $55M Series C financing. The funding will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor (CAR) T …

Read More